Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India flag India · Delayed Price · Currency is INR
24.04
+0.32 (1.35%)
Aug 19, 2026, 3:29 PM IST

Balaxi Pharmaceuticals Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
2,8012,7022,9262,4133,3642,794
Revenue Growth
-5.90%-7.65%21.25%-28.28%20.42%20.77%
Gross Profit
1,2471,1841,2661,1241,293814.24
Operating Income
65.0363.75353.21446.44548.12497.22
Net Income
24.2414.17250.7-23.87459.63476.58
Earnings Per Share
0.450.264.54-0.469.089.53
EPS Growth
--94.35%---4.74%24.96%

Cash & Debt

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
165.43165.43407.03625.72284.6573.77
Total Debt
576.49576.49534.25194.04133.0736.38
Net Cash (Debt)
-411.06-411.06-127.22431.68151.5837.39
Net Cash Growth
---184.78%305.40%-
Net Cash Per Share
-7.58-7.45-2.308.392.990.75

Cash Flow & CapEx

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
--45-350.0348.6660.75341.45
Capital Expenditures
--369.25-211.19-6.93-130.58-53.21
Free Cash Flow
--414.25-561.2341.74-69.83288.23
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
44.51%43.81%43.28%46.58%38.42%29.14%
Operating Margin
2.32%2.36%12.07%18.50%16.29%17.80%
Pretax Margin
2.31%1.96%9.80%0.84%16.92%19.51%
Profit Margin
0.86%0.52%8.57%-0.99%13.66%17.06%
FCF Margin
--15.33%-19.18%1.73%-2.08%10.32%

Valuation

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
53.0561.0612.98-11.727.38
P/FCF Ratio
---120.99-12.20
PS Ratio
0.470.321.112.091.601.26